Q2 2026 saw 4% revenue growth and margin expansion, driven by strong subscription and cloud adoption, with ARR up 6% year-over-year. The acquisition of ArisGlobal strengthens the Life Sciences segment, and full-year guidance is confirmed.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.